Post Profile






Valeant seems determined to make the government angry (VRX)

Valeant Pharmaceuticals has announced that it will increase prices for much of its drug product line, contrary to what company executives told legislators in Congressional hearings earlier this year. From the release: These planned wholesale acquisition price changes, effective October 14, range from 2% to 9%. The changes are aligned with the Committee's commitment that the average annual price increase for Valeant's prescription pharmaceutical products will be set at no greater than single digits and below the 5- year weighted average of the increases within the branded biopharmaceutical industry.
read more

share

Related Posts


Goldman Sachs sold 1.3 million of the Valeant CEO's shares of his company yesterday (VRX)

Business & Finance : Business Insider: Clusterstock

Embattled Canadian drug company Valeant Pharmaceutical's CEO J. Michael Pearson got a collateral call from Goldman Sachs. On April 22, 2014, when Valeant's share price was $206.93, Pearson pledged two million shares to Goldman in ex...

Martin Shkreli All but Gloated Over Huge Drug Price Increases, Memos Show

Business & Finance : DealBook

Documents released by a congressional panel show that Valeant Pharmaceuticals and Turing Pharmaceuticals, Mr. Shkreli’s former company, sometimes raised prices as much as fiftyfold.

Valeant bought a drug that helps terminally ill people die and doubled the price (VRX)

Business & Finance : Business Insider: Clusterstock

Valeant Pharmaceuticals doubled the price of a drug called Seconal, which helps terminally ill patients end their lives peacefully, according to a report from KQED News. Valeant purchased the drug last February, and jacked up the pr...

LIVE: Martin Shkreli, the CEO of Valeant and others face Congress

Business & Finance : Business Insider: Clusterstock

The interim chief executive of pharmaceutical company Valeant and infamous former Turing CEO Martin Shkreli are facing Congress right now. Legislators want them to answer for dramatic drug price increases that impact the lives of Am...

Valeant says it's backing away from its most controversial practice – a week before congressional hearings begin (VRX)

Business & Finance : Business Insider: Clusterstock

Valeant Pharmaceuticals repeated a pledge to back off its practice of hiking the price of off-patent drugs, a week before congressional hearings on the issue begin.In an op-ed on CNBC.com Wednesday, interim CEO Howard Schiller and i...

Comments


Copyright © 2016 Regator, LLC